ClinicalTrials.gg
CompletedNCT00418834Updated May 14, 2024Results posted

Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)

A Phase 3 interventional study of ezetimibe and atorvastatin and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
7th of 97
1,053 · median 148
Started
2007
with 15 others
Phase 3
50 of 98
1 open now
Registered
20th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 7th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 20th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of atorvastatin on lipid lowering.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is age 65 or older
  • Patient is willing to maintain cholesterol lowering diet
  • Patient has hyperlipidemia with LDL level greater than 70 mg/dl or 100 mg/dl depending on their CHD risk category

Exclusion criteria

Exclusion Criteria:

  • A condition which, in the opinion of the investigator, would pose a risk to the patient or interfere with participation in the study
  • Patient is unlikely to be compliant in taking study medication
  • Patient with chronic or unstable medical condition
  • Patient is taking unstable doses of medication
  • Patient drinks more than 2 alcoholic drinks per day
  • Patient has elevations in certain laboratory values (CK, , ALT)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,053 participants (actual)

Study arms

  • Active comparator
    1

    Drug: ezetimibe and atorvastatin · Drug: Placebo (unspecified)

  • Active comparator
    2

    Drug: atorvastatin · Drug: Placebo (unspecified)

Interventions

  • Drugezetimibe and atorvastatin

    Drug pages: Ezetimibe · Atorvastatin

    ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks

  • Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks

  • DrugPlacebo (unspecified)

    Placebo (unspecified) daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 6

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Time frame: Baseline and Week 12

  2. Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6

    Time frame: Week 6

  3. Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12

    Time frame: Week 12

  4. Number of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6

    Time frame: Week 6

  5. Number of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12

    Time frame: Week 12

Other outcomes

  1. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6

    Time frame: Baseline and Week 6

  2. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6

    Time frame: Baseline and Week 6

  4. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Time frame: Baseine and Week 12

  5. Percent Change From Baseline in Total Cholesterol (TC) at Week 6

    Time frame: Baseline and Week 6

  6. Percent Change From Baseline in Total Cholesterol (TC) at Week 12

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline in Triglycerides (TG) at Week 6

    Time frame: Baseline and Week 6

  8. Percent Change From Baseline in Triglycerides (TG) at Week 12

    Time frame: Baseline and Week 12

  9. Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6

    Time frame: Baseline and Week 6

  10. Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12

    Time frame: Baseline and Week 12

  11. Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6

    Time frame: Baseline and Week 6

  12. Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12

    Time frame: Baseline and Week 12

  13. Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    Time frame: Baseline and Week 6

  14. Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12

    Time frame: Baseline and Week 12

  15. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    Time frame: Baseline and Week 6

  16. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12

    Time frame: Baseline and Week 12

  17. Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6

    Time frame: Baseline and Week 6

  18. Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12

    Time frame: Baseline and Week 12

  19. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    Time frame: Baseline and Week 6

  20. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12

    Time frame: Baseline and Week 12

  21. Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6

    Time frame: Baseline and Week 6

  22. Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Oct 6, 2009

Participant flow

Phase III First Patient In: 28-Feb-2007; Last Patient Last Visit: 01-Oct-2008 143 centers worldwide (United States, Canada, Poland, Romania, Ukraine and Russia)

Participant flow — Overall Study
MilestoneAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Started526527
Completed503507
Not completed2320
Withdrew: Adverse event169
Withdrew: Lost to follow-up01
Withdrew: Protocol violation43
Withdrew: Withdrawal by subject37

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in LDL-C at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in LDL-C at Week 6-26.7 (-28.6 to -24.7)-12.8 (-14.8 to -10.9)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -13.8 · 95% CI -16.0 to -11.7(Atorva 10 mg + EZ minus Atorva 20 mg)
SecondaryPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12-22.5 (-25.0 to -19.9)-17.9 (-20.5 to -15.4)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -4.6 · 95% CI -7.4 to -1.8(Atorva 10 mg + EZ minus Atorva 20 mg)
SecondaryNumber of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
Time frame:
Week 6
Reported as:
Number · Participants
Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
ParticipantsAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
<70 mg/dL24492
≥70 mg/dL271423
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.32 · 95% CI 4.52 to 8.84Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg
SecondaryNumber of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12
Time frame:
Week 12
Reported as:
Number · Participants
Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12
ParticipantsAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
<70 mg/dL225164
≥70 mg/dL291345
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 1.87 · 95% CI 1.40 to 2.50Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg / Atorva 40 mg
SecondaryNumber of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6
Time frame:
Week 6
Reported as:
Number · Participants
Number of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6
ParticipantsAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
<100 mg/dL (w/o AVD) and <70 mg/dL (w/ AVD)274127
>100 mg/dL (w/o AVD) and ≥70 mg/dL (w/AVD)241388
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.48 · 95% CI 3.98 to 7.55Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg
SecondaryNumber of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12
Time frame:
Week 12
Reported as:
Number · Participants
Number of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12
ParticipantsAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
<100 mg/dL (w/o AVD) and <70 mg/dL (w/ AVD)255200
≥100 mg/dL (w/o AVD) and ≥70 mg/dL (w/ AVD)261309
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 1.75 · 95% CI 1.32 to 2.31Estimated ratio is the predictive odds of attaining LDL-C target on Atorva 10 mg + EZ versus Atorva 20 mg / Atorva 40 mg
Other pre-specifiedPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 62.5 (1.1 to 4.0)0.7 (-0.8 to 2.1)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): 1.9 · 95% CI 0.3 to 3.5(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 122.4 (0.9 to 3.8)-0.8 (-2.2 to 0.7)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): 3.1 · 95% CI 1.5 to 4.8(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6-23.5 (-25.2 to -21.7)-11.2 (-13.0 to -9.5)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -12.2 · 95% CI -14.2 to -10.3(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame:
Baseine and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12-20.0 (-22.3 to -17.7)-15.8 (-18.1 to -13.5)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -4.2 · 95% CI -6.8 to -1.7(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Total Cholesterol (TC) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol (TC) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Total Cholesterol (TC) at Week 6-15.9 (-17.2 to -14.6)-8.0 (-9.3 to -6.7)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -7.9 · 95% CI -9.4 to -6.5(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Total Cholesterol (TC) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol (TC) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Total Cholesterol (TC) at Week 12-13.6 (-15.2 to -12.0)-11.6 (-13.2 to -10.0)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -2.0 · 95% CI -3.8 to -0.2(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Triglycerides (TG) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Triglycerides (TG) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Triglycerides (TG) at Week 6-12.9 (-14.3 to -9.7)-5.7 (-8.4 to -3.5)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Nonparametric ANCOVA · p = <0.001 · Median difference (final values): -6.2 · 95% CI -9.0 to -3.4(Atorva 10 mg + EZ minus Atorva 20 mg) The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic
Other pre-specifiedPercent Change From Baseline in Triglycerides (TG) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Triglycerides (TG) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Triglycerides (TG) at Week 12-11.8 (-13.7 to -9.3)-8.5 (-11.3 to -7.1)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Nonparametric ANCOVA · p = <0.001 · Median difference (final values): -2.1 · 95% CI -5.2 to 1.0(Atorva 10 mg + EZ minus Atorva 20 mg) The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6-16.8 (-18.5 to -15.1)-7.7 (-9.4 to -6.0)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -9.1 · 95% CI -11.0 to -7.3(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12-14.0 (-16.1 to -11.9)-10.8 (-12.9 to -8.7)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -3.2 · 95% CI -5.5 to -0.9(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6-1.1 (-2.4 to 0.3)-1.7 (-3.0 to -0.3)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = 0.401 · Mean difference (final values): 0.6 · 95% CI -0.9 to 2.1(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 120.7 (-0.7 to 2.1)-2.0 (-3.4 to -0.6)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): 2.7 · 95% CI 1.1 to 4.2(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-16.9 (-18.4 to -15.3)-7.9 (-9.4 to -6.3)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -9.0 · 95% CI -10.7 to -7.3(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12-14.4 (-16.4 to -12.5)-9.8 (-11.8 to -7.9)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -4.6 · 95% CI -6.8 to -2.4(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-27.2 (-29.5 to -25.0)-12.6 (-14.9 to -10.4)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -14.6 · 95% CI -17.0 to -12.2(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12-22.9 (-25.9 to -20.0)-16.0 (-18.9 to -13.1)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -6.9 · 95% CI -10.1 to -3.7(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6-14.8 (-16.6 to -12.9)-5.2 (-7.1 to -3.4)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -9.5 · 95% CI -11.6 to -7.5(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12-13.5 (-15.7 to -11.3)-8.2 (-10.4 to -6.0)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -5.3 · 95% CI -7.7 to -2.9(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-24.0 (-26.2 to -21.8)-11.1 (-13.3 to -8.9)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -12.9 · 95% CI -15.3 to -10.5(Atorva 10 mg + EZ minus Atorva 20 mg)
Other pre-specifiedPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12-20.4 (-23.2 to -17.6)-13.8 (-16.6 to -10.9)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · ANCOVA · p = <0.001 · Mean difference (final values): -6.7 · 95% CI -9.8 to -3.6(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg)
Other pre-specifiedPercent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6-13.5 (-19.6 to -6.8)-10.7 (-17.0 to -3.9)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Longitudinal Data Analysis (LDA) · p = 0.534 · Mean difference (final values): -2.8 · 95% CI -11.9 to 6.4(Atorva 10 mg + EZ minus Atorva 20 mg) Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means.
Other pre-specifiedPercent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12
Percent ChangeAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12-21.7 (-27.3 to -15.6)-14.6 (-20.7 to -8.0)
Statistical analysis
  • Atorva 10 mg + EZ vs Atorva 20 mg / Atorva 40 mg · Longitudinal Data Analysis (LDA) · p = 0.090 · Mean difference (final values): -7.0 · 95% CI -15.6 to 1.6(Atorva 10 mg + EZ minus Atorva 20 mg / Atorva 40 mg) Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorva 10 mg + EZ———
Atorva 20 mg / Atorva 40 mg———
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
Angina pectorisCardiac disorders1/5262/525
Acute myocardial infarctionCardiac disorders1/5261/525
Angina unstableCardiac disorders0/5261/525
Coronary artery diseaseCardiac disorders0/5261/525
Myocardial infarctionCardiac disorders1/5261/525
Abdominal discomfortGastrointestinal disorders0/5261/525
Chest painGeneral disorders0/5261/525
GastroenteritisInfections and infestations0/5261/525
Brain stem haemorrhageNervous system disorders0/5261/525
DizzinessNervous system disorders0/5261/525
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAtorva 10 mg + EZAtorva 20 mg / Atorva 40 mg
HypertensionVascular disorders0/5269/525
Upper respiratory tract infectionInfections and infestations7/5268/525
NasopharyngitisInfections and infestations6/5267/525
HeadacheNervous system disorders7/5267/525
ConstipationGastrointestinal disorders7/5263/525
Back painMusculoskeletal and connective tissue disorders4/5266/525
BronchitisInfections and infestations6/5263/525
Asparate aminotransferase increasedInvestigations2/5265/525
Muscle spasmMusculoskeletal and connective tissue disorders0/5265/525
Blood glucose increasedInvestigations5/5262/525

Baseline characteristics

Age, Continuous
Age, Continuous(years)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
Mean71.2 (65 to 86)71.2 (65 to 92)71.2 (65 to 92)
Sex: Female, Male
Sex: Female, Male(Participants)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
Female277286563
Male249241490
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
White5035051008
Native Hawaiian or Other Pacific Islander011
Asian235
Black211738
Multi-Racial011
Region of Enrollment
Region of Enrollment(Participants)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
North America189197386
Europe337330667
BMI [Body Mass Index (<30, ≥30 kg/m2)]
BMI [Body Mass Index (<30, ≥30 kg/m2)](Participants)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
<30 kg/m2359362721
≥30 kg/m2165165330
Missing202
Apo lipoprotein A-I (Apo A-I)
Apo lipoprotein A-I (Apo A-I)(mg/dL)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
Mean164.3 ± 28.7164.4 ± 26.8164.4 ± 27.7
Apo lipoprotein B (Apo B)
Apo lipoprotein B (Apo B)(mg/dL)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
Mean103.6 ± 22.8101.8 ± 21.4102.7 ± 22.1
Apo lipoprotein B (Apo B):Apo lipoprotein A-I (Apo A-I) Ratio
Apo lipoprotein B (Apo B):Apo lipoprotein A-I (Apo A-I) Ratio(Ratio)Atorva 10 mg + EZAtorva 20 mg / Atorva 40 mgTotal
Mean0.6 ± 0.20.6 ± 0.20.6 ± 0.2

9 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Zieve F, Wenger NK, Ben-Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol. 2010 Mar 1;105(5):656-63. doi: 10.1016/j.amjcard.2009.10.029. Epub 2009 Dec 24. PubMed 20185012 ↗
  • Constance C, Ben-Yehuda O, Wenger NK, Zieve F, Lin J, Hanson ME, Lowe RS, Tershakovec AM. Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects >/=65 years. Lipids Health Dis. 2014 Jan 13;13:13. doi: 10.1186/1476-511X-13-13. PubMed 24411003 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2007
First posted
Jan 5, 2007
Start
Jan 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Oct 6, 2009
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00418834
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 5, 2007
Start date
Jan 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Oct 6, 2009
Last update
May 14, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion